Fig. 4From: Cost utility analysis of cryopreserved amniotic membrane versus topical cyclosporine for the treatment of moderate to severe dry eye syndromeSensitivity analysis showing that if productivity costs are < 161 day, then Cyclosporine A (Restasis) would be the less expensive option for treatmentBack to article page